<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682175</url>
  </required_header>
  <id_info>
    <org_study_id>08-169</org_study_id>
    <nct_id>NCT00682175</nct_id>
  </id_info>
  <brief_title>Metabolic Derangements in Acute Heart Failure Syndrome</brief_title>
  <official_title>Metabolic Derangements in Acute Heart Failure Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the association of both neurohormonal and hemodynamic alterations associated&#xD;
      with metabolic abnormalities in acute heart failure syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Project not initiated&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Adult (age &gt; 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (age &gt; 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22) with&#xD;
        Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery catheter for&#xD;
        hemodynamically guided therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (age &gt; 18 yrs) patients admitted to the Heart Failure Intensive Care Unit (H22)&#xD;
             with Acute Heart Failure Syndrome (AHFS) requiring placement of a Pulmonary Artery&#xD;
             catheter for hemodynamically guided therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Congenital Heart Disease.&#xD;
&#xD;
          -  Acute HF in the setting of acute myocardial infarction.&#xD;
&#xD;
          -  Severe Anemia&#xD;
&#xD;
          -  Patients listed for cardiac transplantation.&#xD;
&#xD;
          -  Terminal Malignancy, AIDS or CNS disease.&#xD;
&#xD;
          -  Concomitant sepsis, ARDS, trauma, aortic dissection, or pericardial tamponade&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Sokos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>March 25, 2009</last_update_submitted>
  <last_update_submitted_qc>March 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>George Sokos, MD</name_title>
    <organization>Cleveland Clinic Foundation</organization>
  </responsible_party>
  <keyword>Congestive Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

